Whole Exome Sequencing (WES) based Biomarker Discovery Service
Whole Exome sequencing (WES) is efficient in discovering novel gene biomarkers in clinical evaluation. Based on the comprehensive analysis of WES data from our cutting-edge SuPrecision™, Creative Biolabs is proficient in developing genome-based biomarkers to guide precision cancer treatment. We can provide a rigorous proof of principle for developing a precision medicine approach to clinical cancer care with the capability to identify novel biomarkers of response and therapeutic targets.
The Background of Cancer Therapy
The rapid development of next-generation sequencing (NGS) analyses providing an unprecedented potential to reach personalized medicine has revolutionized biomedical research and cancer genomics. NGS has provided enormous insight into the genomic landscape of several tumor types, illuminating molecularly defined tumor subtypes, identifying new druggable targets, and providing insights into the heterogeneity of many tumors. WES analyses in tumor-normal tissue pair samples have become a fast and accurate method for sequencing approximate genes of human exome and identifying cancer driver genes for each cancer type. Although advances have been made in decisive therapies, including tumor node metastasis staging therapy based nonspecific multimodal therapy and single-gene testing for identifying mutated or amplified genes, the progress is still slow in fighting against cancer. Although approved antibody for HER2-positive advanced or metastatic gastric cancer increases response rate and improves overall survival, there’s still an urgently need of robust biomarkers to predict therapeutic resistance. With rapidly advancing technologies and decreasing costs, the use of genomic information to select the most effective treatment options for patients and minimize adverse effects will soon become routinely feasible.
Biomarkers Identification Service at Creative Biolabs
Creative Biolabs has developed an evidence-based precision medicine analysis approach for patients with a tumor or treatment-resistant disease. WES is performed in matched tumor-normal tissues. A comprehensive computational pipeline has been developed and validated by our seasoned scientists for the analysis of WES data. We can provide a comprehensive understanding on how WES affects therapeutic decision making and to identify novel biomarkers of response.
Key Advantages of Biomarkers Identification Service at Creative Biolabs Include but Are Not Limited to:
- One-stop solution for WES projects
- A comprehensive computational pipeline
- Cutting-edge SuPrecision™
- Detailed project report
Creative Biolabs provides a one-stop solution for WES projects from experimental design to advanced bioinformatics analysis. By identifying cancer driver genes involved in tumorigenesis, WES analysis in Creative Biolabs enables the development of robust biomarkers and novel therapeutic targets to reach precision cancer treatment. Our scientists can provide the best service for the identification of novel biomarkers at the most competitive price.
Please contact us for more information and a detailed quote.
Resources
Infographics
Podcast
Note: Our sequencing services are for Research Use Only. Not For Clinical Diagnosis.
Related Services:
- TMB Analysis for Checkpoint Immunotherapy Response
- WES based Variant Analysis
- WES based Structural Variant Detection
- WES based CNV Detection
- WES based Tumor-Specific Neoantigen Discovery
- Personal Tumor-Specific Neoantigen Vaccine Development
- MRD Monitoring
- Microsatellite Instability Analysis
- Immune Repertoire Germline Gene & Allele Identification
- One-Stop Cancer 3D Modeling
- Circle-Seq based eccDNA Identification
- RNA-Seq based Tumor Microenvironment Analysis
Online Inquiry
